Tablets containing Selegiline Hydrochloride 5mg.
Selegiline is a selective MAO-B inhibitor which prevents dopamine breakdown in the brain. It also inhibits the re-uptake of dopamine at the pre-synaptic dopamine receptor. These effects potentiate dopaminergic function in the brain and help to even out and prolong the effect of exogenous or endogenous dopamine.
Recent studies have demonstrated that use of Selegiline in previously untreated patients can delay the development of disability and prolong the time before levodopa therapy is required. Selegiline potentiates and prolongs the effect of levodopa in the treatment of parkinsonism. The addition of Selegiline to levodopa (with or without decarboxylase inhibitor) therapy helps to alleviate dose related fluctuations and end-of-dose deterioration. At a later stage in the disease it can also smooth the symptoms of the on/off effect.
Unlike conventional MAO inhibitors, which inhibit both the MAO-A and MAO-B enzyme. Selegiline is a specific MAO-B inhibitor and can be given safely with levodopa. There are no dietary restrictions associated with Selegiline treatment, i.e. it does not cause the so called cheese effect.
SELEGOS is indicated for the treatment of Parkinson's disease or symptomatic parkinsonism.
SELEGOS may be used alone in early Parkinson's disease to delay, the need for levodopa (with or without decarboxylase inhibitor). SELEGOS may also be used as an adjunct to levodopa (with or without decarboxylase inhibitor).
SELEGOS 10mg (2 tablets) daily either alone or as an adjunct to levodopa or levodopa/peripheral decarboxylase inhibitor.
SELEGOS may be administered either as a single dose in the morning or in two divided doses of 5mg taken at breakfast and lunch.
When SELEGOS is added to a levodopa regimen it is possible to reduce the levodopa dosage by an average of 30 percent.
Treatment of overdosage: SELEGOS has such a low toxicity that no overdosage problems have been encountered. Selegiline hydrochloride is rapidly metabolised and the metabolites rapidly excreted. In cases of suspected overdosage the patient should be kept under observation for 24-48 hours.
Because Selegiline potentiates the effects of levodopa the side effects of levodopa might be emphasised, particularly when the patient is on a very high dosage of levodopa. The addition of SELEGOS to maximal doses of levodopa may cause involuntary movement and/or agitation. Such side effects disappear when the levodopa dosage is decreased. Levodopa treatment can be reduced by an average of 30 percent when SELEGOS is added to the treatment. When an optimal levodopa dose has been established, the side effects of the combination have been found to be fewer than for levodopa alone.
Use in pregnancy: SELEGOS is indicated for parkinsonism.
This tends to be a disease of the elderly past child-bearing age. No work has been done to assess the effects of Selegiline on pregnancy and lactation, thus it should not be used in such cases.
Hypotension and nausea have been reported as isolated symptoms associated with SELEGOS treatment. Confusion or psychosis have also been reported.
Selegiline should not be given in conjunction with non-specific monoamine oxidase inhibitors.
Store in a cool and dry place protected from light.
N04BD01 - selegiline ; Belongs to the class of dopaminergic agents, monoamine oxidase B inhibitors. Used in the management of Parkinson's disease.